Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer

被引:28
|
作者
Xun Shangguan [1 ]
Ma, Zehua [2 ]
Yu, Minghao [1 ]
Ding, Jie [1 ]
Xue, Wei [2 ]
Qi, Jun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Urol, Sch Med, Shanghai 200092, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
关键词
CHOLESTEROL-SYNTHESIS; ANDROGEN RECEPTOR; MONOOXYGENASE; INHIBITION; MECHANISMS; PATHWAY; PTEN; PROGRESSION; THERAPIES; ENZYME;
D O I
10.1158/0008-5472.CAN-21-3822
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Considering the dismal prognosis of castration-resistant prostate cancer (CRPC), it is critical to identify novel therapeutic targets in this disease. Malignant cells have metabolic dependencies distinct from their healthy counterparts, resulting in therapeutic vulnerabilities. Although PTEN and TP53 are the most frequently comutated or codeleted driver genes in lethal CRPC, the metabolic dependencies underlying PTEN/p53 deficiency-driven CRPC for therapeutic intervention remain largely elusive. In this study, PTEN/p53 deficient tumors were determined to be reliant on cholesterol metabolism. Moreover, PTEN/p53 deficiency transcriptionally upregulated squalene epoxidase (SQLE) via activation of sterol regulatory element-binding protein 2 (SREBP2). In addition, PTEN deficiency enhanced the protein stability of SQLE by inhibiting the PI3K/Akt/GSK3 beta-mediated proteasomal pathway. Consequently, SQLE increased cholesterol biosynthesis to facilitate tumor cell growth and survival. Pharmacologic blockade of SQLE with FR194738 profoundly suppressed the invasive program of CRPC. Collectively, these results demonstrate a synergistic relationship between SQLE and PTEN/p53 deficiency in CRPC development and progression. Therefore, pharmacologic interventions targeting SQLE may hold promise for the treatment of patients with CRPC. Significance: This study reveals PTEN and p53 deficiency confers a dependence on SQLE-mediated cholesterol metabolism, providing insights for new therapeutic strategies for treating castration-resistant prostate cancer.
引用
收藏
页码:3032 / 3044
页数:13
相关论文
共 50 条
  • [41] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [42] Effect of dutasteride on castration-resistant prostate cancer
    Azuma, Takeshi
    Matayoshi, Yukihide
    Sato, Yujiro
    Nagase, Yasuhi
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) : 133 - 136
  • [43] Leading causes of castration-resistant prostate cancer
    Lu, Mingqian
    Lu, Hongda
    Kong, Qingzhi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (04) : 425 - 432
  • [44] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580
  • [45] Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
    Mostaghel, Elahe A.
    Montgomery, Bruce
    Nelson, Peter S.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (03) : 251 - 257
  • [46] Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer
    Flanagan, J.
    Gray, P. Kathryn
    Hahn, N.
    Hayes, J.
    Myers, L. J.
    Carney-Doebbeling, C.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2011, 22 (04) : 801 - 807
  • [47] About sorafenib in castration-resistant prostate cancer
    Colloca, G.
    Checcaglini, F.
    Venturino, A.
    ANNALS OF ONCOLOGY, 2008, 19 (10)
  • [48] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [49] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [50] Sequencing of agents in castration-resistant prostate cancer
    Lorente, David
    Mateo, Joaquin
    Perez-Lopez, Raquel
    de Bono, Johann S.
    Attard, Gerhardt
    LANCET ONCOLOGY, 2015, 16 (06): : E279 - E292